Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
110 studies found for:    "Small intestine cancer"
Show Display Options
Rank Status Study
1 Unknown  Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
Condition: Small Intestine Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
2 Active, not recruiting Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
Conditions: Small Intestine Adenocarcinoma;   Recurrent Small Intestine Cancer
Interventions: Drug: capecitabine;   Drug: irinotecan hydrochloride;   Drug: oxaliplatin
3 Withdrawn Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis
Conditions: Colorectal Cancer;   Small Intestine Cancer
Intervention: Drug: exisulind
4 Completed Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer
Conditions: Carcinoma of the Appendix;   Colorectal Cancer;   Small Intestine Cancer
Interventions: Drug: capecitabine;   Drug: oxaliplatin
5 Terminated Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
Conditions: Non-melanomatous Skin Cancer;   Pancreatic Cancer;   Small Intestine Cancer;   Testicular Germ Cell Tumor
Interventions: Genetic: in situ hybridization;   Genetic: protein expression analysis;   Other: immunologic technique
6 Recruiting Enteroscopy for Early Diagnosis of Tumors in Celiac Disease
Conditions: Small Intestine Cancer;   Celiac Disease
Intervention: Device: Capsule endoscopy, double balloon enteroscopy sequential use
7 Active, not recruiting Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Procedure: radionuclide imaging;   Radiation: indium In 111-labeled autologous peripheral blood mononuclear cells;   Radiation: indium In 111-labeled autologous polymorphonuclear leukocytes
8 Unknown  High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Drug: carmustine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: methotrexate;   Drug: prednisolone;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: biopsy;   Procedure: peripheral blood stem cell transplantation
9 Unknown  Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Biological: alemtuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisolone;   Drug: vincristine sulfate;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Completed
Has Results
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Drug: vorinostat;   Other: Correlative studies
11 Completed Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate
12 Completed Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Intervention: Biological: pegylated interferon alfa
13 Completed Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Intervention: Biological: visilizumab
14 Unknown  Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
Conditions: Ovarian Cancer;   Sarcoma;   Small Intestine Cancer
Interventions: Drug: brostallicin;   Drug: doxorubicin hydrochloride
15 Completed Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Conditions: Ovarian Cancer;   Sarcoma;   Small Intestine Cancer
Interventions: Biological: filgrastim;   Drug: docetaxel;   Drug: gemcitabine hydrochloride
16 Completed 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: alvespimycin hydrochloride
17 Completed Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: etaracizumab
18 Completed VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: laromustine
19 Completed S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: BMS-247550
20 Completed CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: lenalidomide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.